Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Jupiter Neurosciences Inc (JUNS)

Jupiter Neurosciences Inc (JUNS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering GlobeNewswire - Thu May 21, 4:15PM CDT

Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position  Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:...

JUNS : 0.2378 (-12.19%)
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering GlobeNewswire - Wed May 20, 1:38PM CDT

Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders...

JUNS : 0.2378 (-12.19%)
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million GlobeNewswire - Wed May 20, 7:15AM CDT

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“ PharmAla ” or the “ Company ”), a global leader in the research, development, and manufacturing...

MDXXF : 0.1058 (-6.70%)
JUNS : 0.2378 (-12.19%)
MDMA.CN : 0.1450 (-9.38%)
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech GlobeNewswire - Wed May 20, 6:38AM CDT

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May...

JUNS : 0.2378 (-12.19%)
MDXXF : 0.1058 (-6.70%)
MDMA.CN : 0.1450 (-9.38%)
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit Newsfile - Mon May 4, 10:30AM CDT

Jupiter, Florida--(Newsfile Corp. - May 4, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, announced...

JUNS : 0.2378 (-12.19%)
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 Newsfile - Mon Apr 13, 7:04PM CDT

Jupiter, Florida--(Newsfile Corp. - April 13, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, will...

JUNS : 0.2378 (-12.19%)
Jupiter Neurosciences Investor News: Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS Business Wire - Mon Apr 13, 6:00PM CDT

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (NASDAQ: JUNS) resulting from...

JUNS : 0.2378 (-12.19%)
Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS Business Wire - Sun Apr 12, 6:16PM CDT

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (NASDAQ: JUNS) resulting from...

JUNS : 0.2378 (-12.19%)
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board GlobeNewswire - Tue Apr 7, 7:00AM CDT

New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia ™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable...

JUNS : 0.2378 (-12.19%)
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2 GlobeNewswire - Tue Mar 31, 11:00AM CDT

JUPITER, FL, March 31, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL ™ , a patented...

JUNS : 0.2378 (-12.19%)

Barchart Exclusives

Wall Street Is Warming Back Up to CoreWeave Stock. Long-Term Demand Is Helping. Barchart - 44 minutes ago
The firm expects the company to reach profitability by 2028. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.